| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Tomography, X-Ray Computed | 142 | 2023 | 2324 | 11.600 |
Why?
|
| Coronary Artery Disease | 68 | 2022 | 696 | 10.870 |
Why?
|
| Lung Neoplasms | 74 | 2023 | 1173 | 8.670 |
Why?
|
| Coronary Angiography | 57 | 2022 | 866 | 7.670 |
Why?
|
| Solitary Pulmonary Nodule | 28 | 2023 | 77 | 5.970 |
Why?
|
| Coronary Vessels | 32 | 2022 | 313 | 5.950 |
Why?
|
| Computed Tomography Angiography | 25 | 2022 | 424 | 5.230 |
Why?
|
| Pulmonary Disease, Chronic Obstructive | 20 | 2023 | 207 | 4.660 |
Why?
|
| Vascular Calcification | 22 | 2021 | 131 | 4.650 |
Why?
|
| Coronary Stenosis | 16 | 2022 | 246 | 4.250 |
Why?
|
| Myocardial Perfusion Imaging | 17 | 2022 | 100 | 4.170 |
Why?
|
| Early Detection of Cancer | 48 | 2023 | 454 | 4.130 |
Why?
|
| Calcinosis | 31 | 2020 | 241 | 4.100 |
Why?
|
| Multiple Pulmonary Nodules | 18 | 2023 | 41 | 3.940 |
Why?
|
| Radiographic Image Interpretation, Computer-Assisted | 33 | 2023 | 373 | 3.260 |
Why?
|
| Pulmonary Emphysema | 14 | 2023 | 71 | 3.240 |
Why?
|
| Radiation Dosage | 27 | 2023 | 419 | 2.890 |
Why?
|
| Lung | 32 | 2023 | 849 | 2.580 |
Why?
|
| Phantoms, Imaging | 20 | 2019 | 189 | 2.430 |
Why?
|
| Plaque, Atherosclerotic | 10 | 2021 | 125 | 2.410 |
Why?
|
| Calcium | 11 | 2023 | 929 | 2.350 |
Why?
|
| Predictive Value of Tests | 45 | 2022 | 1465 | 2.200 |
Why?
|
| Chest Pain | 8 | 2022 | 151 | 2.020 |
Why?
|
| Humans | 217 | 2023 | 68618 | 2.000 |
Why?
|
| Emphysema | 8 | 2023 | 32 | 1.980 |
Why?
|
| Coronary Circulation | 9 | 2019 | 136 | 1.760 |
Why?
|
| Middle Aged | 124 | 2022 | 21147 | 1.720 |
Why?
|
| Cardiovascular Diseases | 15 | 2022 | 940 | 1.660 |
Why?
|
| Myocardial Ischemia | 12 | 2022 | 172 | 1.640 |
Why?
|
| Fractional Flow Reserve, Myocardial | 8 | 2022 | 137 | 1.540 |
Why?
|
| Aged | 95 | 2022 | 14862 | 1.520 |
Why?
|
| Reproducibility of Results | 42 | 2021 | 2077 | 1.510 |
Why?
|
| Netherlands | 30 | 2021 | 68 | 1.460 |
Why?
|
| Male | 133 | 2022 | 37321 | 1.430 |
Why?
|
| Mass Screening | 26 | 2022 | 843 | 1.410 |
Why?
|
| Multidetector Computed Tomography | 12 | 2023 | 60 | 1.380 |
Why?
|
| Female | 120 | 2022 | 38074 | 1.330 |
Why?
|
| Adipose Tissue | 4 | 2022 | 221 | 1.290 |
Why?
|
| Isolated Heart Preparation | 4 | 2018 | 8 | 1.290 |
Why?
|
| Radiography, Thoracic | 4 | 2020 | 99 | 1.250 |
Why?
|
| Radiology | 6 | 2022 | 97 | 1.230 |
Why?
|
| Smoking | 25 | 2023 | 1452 | 1.190 |
Why?
|
| Contrast Media | 18 | 2021 | 595 | 1.180 |
Why?
|
| Risk Factors | 43 | 2022 | 5731 | 1.080 |
Why?
|
| Atherosclerosis | 5 | 2022 | 204 | 1.070 |
Why?
|
| Electrocardiography | 16 | 2021 | 601 | 1.060 |
Why?
|
| Severity of Illness Index | 23 | 2022 | 1851 | 1.030 |
Why?
|
| Machine Learning | 4 | 2022 | 170 | 0.970 |
Why?
|
| Cardiac-Gated Imaging Techniques | 8 | 2020 | 60 | 0.930 |
Why?
|
| Retrospective Studies | 37 | 2022 | 7277 | 0.910 |
Why?
|
| Risk Assessment | 24 | 2022 | 2007 | 0.860 |
Why?
|
| Magnetic Resonance Angiography | 5 | 2019 | 181 | 0.860 |
Why?
|
| Tomography Scanners, X-Ray Computed | 3 | 2017 | 32 | 0.840 |
Why?
|
| Iodine | 3 | 2019 | 42 | 0.820 |
Why?
|
| Coronary Disease | 7 | 2014 | 358 | 0.820 |
Why?
|
| General Practitioners | 1 | 2022 | 10 | 0.820 |
Why?
|
| Adenosine | 5 | 2019 | 165 | 0.820 |
Why?
|
| Population Surveillance | 2 | 2021 | 285 | 0.810 |
Why?
|
| Cardiomyopathy, Hypertrophic | 3 | 2020 | 116 | 0.800 |
Why?
|
| Algorithms | 17 | 2022 | 1196 | 0.740 |
Why?
|
| Sensitivity and Specificity | 25 | 2021 | 1753 | 0.730 |
Why?
|
| Cardiomyopathies | 3 | 2018 | 167 | 0.730 |
Why?
|
| Magnetic Resonance Imaging | 13 | 2022 | 2223 | 0.720 |
Why?
|
| Aortic Valve Insufficiency | 1 | 2020 | 47 | 0.700 |
Why?
|
| Cardiac Imaging Techniques | 5 | 2020 | 35 | 0.660 |
Why?
|
| Artificial Intelligence | 6 | 2022 | 159 | 0.650 |
Why?
|
| Myocardial Infarction | 10 | 2019 | 807 | 0.640 |
Why?
|
| Radiography, Dual-Energy Scanned Projection | 4 | 2013 | 92 | 0.630 |
Why?
|
| Prognosis | 15 | 2022 | 2093 | 0.610 |
Why?
|
| Asthma | 1 | 2022 | 345 | 0.610 |
Why?
|
| Hemodynamics | 4 | 2019 | 705 | 0.580 |
Why?
|
| Prospective Studies | 25 | 2023 | 3705 | 0.570 |
Why?
|
| Cognition | 1 | 2021 | 513 | 0.570 |
Why?
|
| Aortic Diseases | 4 | 2013 | 113 | 0.560 |
Why?
|
| Aortography | 2 | 2017 | 72 | 0.560 |
Why?
|
| Aged, 80 and over | 21 | 2021 | 4848 | 0.550 |
Why?
|
| Follow-Up Studies | 19 | 2020 | 3259 | 0.530 |
Why?
|
| Blood Flow Velocity | 6 | 2018 | 172 | 0.520 |
Why?
|
| Disease Models, Animal | 5 | 2018 | 2550 | 0.510 |
Why?
|
| Organ Culture Techniques | 1 | 2015 | 122 | 0.500 |
Why?
|
| Belgium | 14 | 2020 | 18 | 0.500 |
Why?
|
| Diabetic Angiopathies | 1 | 2016 | 203 | 0.490 |
Why?
|
| Incidence | 17 | 2020 | 1603 | 0.480 |
Why?
|
| Magnetic Resonance Imaging, Cine | 5 | 2019 | 83 | 0.460 |
Why?
|
| Carotid Artery Diseases | 3 | 2022 | 83 | 0.450 |
Why?
|
| Software | 11 | 2021 | 418 | 0.450 |
Why?
|
| Imaging, Three-Dimensional | 5 | 2019 | 333 | 0.450 |
Why?
|
| Image Processing, Computer-Assisted | 6 | 2020 | 689 | 0.430 |
Why?
|
| Positron-Emission Tomography | 4 | 2018 | 160 | 0.430 |
Why?
|
| Pericardium | 1 | 2013 | 97 | 0.430 |
Why?
|
| Atrial Fibrillation | 3 | 2022 | 249 | 0.430 |
Why?
|
| Heart | 10 | 2022 | 850 | 0.420 |
Why?
|
| Adult | 27 | 2021 | 21403 | 0.420 |
Why?
|
| Precancerous Conditions | 2 | 2022 | 74 | 0.390 |
Why?
|
| Multimodal Imaging | 3 | 2018 | 62 | 0.380 |
Why?
|
| Coffee | 3 | 2017 | 18 | 0.370 |
Why?
|
| Cone-Beam Computed Tomography | 3 | 2020 | 52 | 0.350 |
Why?
|
| Smokers | 3 | 2022 | 200 | 0.350 |
Why?
|
| Prevalence | 7 | 2021 | 1619 | 0.350 |
Why?
|
| Exercise Test | 5 | 2019 | 242 | 0.340 |
Why?
|
| Europe | 7 | 2020 | 196 | 0.340 |
Why?
|
| Bronchi | 2 | 2022 | 59 | 0.340 |
Why?
|
| Clinical Competence | 1 | 2014 | 657 | 0.340 |
Why?
|
| Registries | 5 | 2022 | 733 | 0.330 |
Why?
|
| Heart Rate | 4 | 2018 | 568 | 0.330 |
Why?
|
| Breast Neoplasms | 4 | 2021 | 1536 | 0.330 |
Why?
|
| Sus scrofa | 3 | 2018 | 74 | 0.330 |
Why?
|
| Gadolinium | 3 | 2021 | 88 | 0.320 |
Why?
|
| Radiation Exposure | 3 | 2018 | 84 | 0.320 |
Why?
|
| Time Factors | 11 | 2018 | 4655 | 0.310 |
Why?
|
| Vasodilator Agents | 3 | 2019 | 138 | 0.310 |
Why?
|
| Cocaine-Related Disorders | 1 | 2013 | 504 | 0.310 |
Why?
|
| Myocardium | 8 | 2019 | 1204 | 0.300 |
Why?
|
| Angina Pectoris | 3 | 2022 | 61 | 0.300 |
Why?
|
| Pandemics | 2 | 2022 | 352 | 0.300 |
Why?
|
| Patient Preference | 2 | 2018 | 57 | 0.290 |
Why?
|
| Practice Guidelines as Topic | 4 | 2019 | 772 | 0.290 |
Why?
|
| Randomized Controlled Trials as Topic | 4 | 2022 | 931 | 0.290 |
Why?
|
| Signal-To-Noise Ratio | 3 | 2017 | 93 | 0.280 |
Why?
|
| Percutaneous Coronary Intervention | 3 | 2017 | 137 | 0.280 |
Why?
|
| Hypertension | 1 | 2016 | 1535 | 0.280 |
Why?
|
| Caffeine | 2 | 2017 | 81 | 0.280 |
Why?
|
| Organometallic Compounds | 2 | 2019 | 95 | 0.280 |
Why?
|
| Heart Valve Diseases | 2 | 2019 | 123 | 0.280 |
Why?
|
| Airway Remodeling | 3 | 2015 | 7 | 0.270 |
Why?
|
| Catheter Ablation | 2 | 2019 | 229 | 0.270 |
Why?
|
| Logistic Models | 6 | 2022 | 1420 | 0.260 |
Why?
|
| Aortic Valve | 2 | 2019 | 249 | 0.260 |
Why?
|
| Spinal Fractures | 2 | 2016 | 43 | 0.250 |
Why?
|
| Models, Cardiovascular | 3 | 2017 | 133 | 0.250 |
Why?
|
| Societies, Medical | 4 | 2020 | 403 | 0.250 |
Why?
|
| Angiography, Digital Subtraction | 2 | 2017 | 63 | 0.250 |
Why?
|
| Observer Variation | 8 | 2021 | 330 | 0.240 |
Why?
|
| Probability | 4 | 2018 | 245 | 0.240 |
Why?
|
| Bone Density | 2 | 2016 | 159 | 0.240 |
Why?
|
| Radiographic Image Enhancement | 3 | 2014 | 208 | 0.240 |
Why?
|
| Liver Neoplasms | 2 | 2019 | 334 | 0.240 |
Why?
|
| Diagnosis, Differential | 6 | 2020 | 1140 | 0.240 |
Why?
|
| Tumor Burden | 5 | 2020 | 132 | 0.240 |
Why?
|
| Automation | 2 | 2014 | 45 | 0.230 |
Why?
|
| China | 5 | 2022 | 138 | 0.230 |
Why?
|
| Tomography, Spiral Computed | 2 | 2018 | 57 | 0.230 |
Why?
|
| Decision Making | 3 | 2018 | 410 | 0.230 |
Why?
|
| Diagnosis, Computer-Assisted | 2 | 2014 | 75 | 0.220 |
Why?
|
| Case-Control Studies | 9 | 2019 | 1553 | 0.220 |
Why?
|
| Constriction, Pathologic | 2 | 2021 | 236 | 0.210 |
Why?
|
| Organ Size | 4 | 2016 | 242 | 0.210 |
Why?
|
| Gadolinium DTPA | 4 | 2019 | 48 | 0.210 |
Why?
|
| Radiotherapy Planning, Computer-Assisted | 2 | 2021 | 36 | 0.210 |
Why?
|
| Rheology | 1 | 2022 | 25 | 0.210 |
Why?
|
| Regression Analysis | 3 | 2021 | 737 | 0.210 |
Why?
|
| X-Rays | 1 | 2022 | 56 | 0.210 |
Why?
|
| Pragmatic Clinical Trials as Topic | 1 | 2022 | 9 | 0.210 |
Why?
|
| Linear Models | 5 | 2017 | 521 | 0.210 |
Why?
|
| Cross-Sectional Studies | 4 | 2021 | 2279 | 0.200 |
Why?
|
| Sinus of Valsalva | 1 | 2022 | 9 | 0.200 |
Why?
|
| Journal Impact Factor | 1 | 2022 | 12 | 0.200 |
Why?
|
| Aortic Rupture | 1 | 2022 | 32 | 0.200 |
Why?
|
| Microwaves | 2 | 2019 | 31 | 0.200 |
Why?
|
| Reference Values | 2 | 2020 | 579 | 0.200 |
Why?
|
| Heart Ventricles | 5 | 2021 | 738 | 0.200 |
Why?
|
| Odds Ratio | 7 | 2022 | 880 | 0.200 |
Why?
|
| Breath Holding | 1 | 2021 | 8 | 0.200 |
Why?
|
| Multicenter Studies as Topic | 1 | 2022 | 186 | 0.200 |
Why?
|
| Aortic Aneurysm | 1 | 2022 | 77 | 0.200 |
Why?
|
| Neoadjuvant Therapy | 1 | 2021 | 104 | 0.190 |
Why?
|
| Neoplasms, Radiation-Induced | 1 | 2022 | 79 | 0.190 |
Why?
|
| Quality of Life | 4 | 2022 | 1515 | 0.190 |
Why?
|
| Feasibility Studies | 3 | 2020 | 652 | 0.190 |
Why?
|
| Chi-Square Distribution | 5 | 2017 | 546 | 0.190 |
Why?
|
| Esophageal Neoplasms | 1 | 2021 | 150 | 0.180 |
Why?
|
| Seasons | 1 | 2021 | 129 | 0.180 |
Why?
|
| False Positive Reactions | 3 | 2020 | 95 | 0.180 |
Why?
|
| Dobutamine | 3 | 2005 | 25 | 0.180 |
Why?
|
| ROC Curve | 6 | 2020 | 392 | 0.180 |
Why?
|
| Multivariate Analysis | 6 | 2017 | 1046 | 0.170 |
Why?
|
| Small Cell Lung Carcinoma | 2 | 2016 | 17 | 0.170 |
Why?
|
| Perfusion | 2 | 2021 | 131 | 0.170 |
Why?
|
| Preoperative Care | 2 | 2019 | 275 | 0.170 |
Why?
|
| Alcohol Drinking | 2 | 2008 | 805 | 0.170 |
Why?
|
| Image Enhancement | 2 | 2017 | 143 | 0.170 |
Why?
|
| Acute Disease | 3 | 2019 | 658 | 0.170 |
Why?
|
| Animals | 7 | 2018 | 20881 | 0.160 |
Why?
|
| Cryosurgery | 1 | 2019 | 53 | 0.160 |
Why?
|
| Radionuclide Imaging | 2 | 2017 | 166 | 0.160 |
Why?
|
| Uterine Cervical Neoplasms | 1 | 2022 | 300 | 0.160 |
Why?
|
| Hematologic Tests | 1 | 2018 | 24 | 0.160 |
Why?
|
| Breath Tests | 1 | 2018 | 23 | 0.160 |
Why?
|
| Pulmonary Veins | 1 | 2019 | 56 | 0.160 |
Why?
|
| Betacoronavirus | 1 | 2020 | 116 | 0.160 |
Why?
|
| Equipment Design | 2 | 2017 | 500 | 0.160 |
Why?
|
| Magnetic Resonance Spectroscopy | 1 | 2020 | 346 | 0.160 |
Why?
|
| Radiography, Interventional | 1 | 2019 | 49 | 0.160 |
Why?
|
| Neoplasm Staging | 5 | 2020 | 800 | 0.160 |
Why?
|
| Surgery, Computer-Assisted | 1 | 2019 | 52 | 0.160 |
Why?
|
| Tomography, Emission-Computed, Single-Photon | 2 | 2018 | 137 | 0.160 |
Why?
|
| Nuclear Medicine | 1 | 2018 | 9 | 0.160 |
Why?
|
| Diathermy | 1 | 2018 | 5 | 0.160 |
Why?
|
| Transcatheter Aortic Valve Replacement | 1 | 2019 | 90 | 0.160 |
Why?
|
| Heart Conduction System | 1 | 2019 | 119 | 0.150 |
Why?
|
| Robotic Surgical Procedures | 1 | 2019 | 49 | 0.150 |
Why?
|
| Forced Expiratory Volume | 5 | 2017 | 87 | 0.150 |
Why?
|
| Purinergic P1 Receptor Antagonists | 1 | 2017 | 10 | 0.150 |
Why?
|
| Iopamidol | 2 | 2014 | 37 | 0.150 |
Why?
|
| Early Diagnosis | 2 | 2016 | 122 | 0.150 |
Why?
|
| Aortic Valve Stenosis | 1 | 2019 | 177 | 0.150 |
Why?
|
| Swine | 2 | 2018 | 672 | 0.150 |
Why?
|
| Drug-Related Side Effects and Adverse Reactions | 1 | 2019 | 148 | 0.150 |
Why?
|
| Disease Progression | 5 | 2018 | 1038 | 0.150 |
Why?
|
| Fibrosis | 5 | 2021 | 371 | 0.150 |
Why?
|
| Ioxaglic Acid | 1 | 2017 | 1 | 0.150 |
Why?
|
| Coronavirus Infections | 1 | 2020 | 143 | 0.140 |
Why?
|
| Pneumonia, Viral | 1 | 2020 | 154 | 0.140 |
Why?
|
| Cicatrix | 1 | 2017 | 60 | 0.140 |
Why?
|
| Receptors, Interleukin-6 | 1 | 2016 | 4 | 0.140 |
Why?
|
| Iohexol | 2 | 2018 | 82 | 0.140 |
Why?
|
| Echocardiography | 1 | 2020 | 515 | 0.140 |
Why?
|
| Acute Pain | 2 | 2016 | 35 | 0.140 |
Why?
|
| Spleen | 1 | 2017 | 301 | 0.140 |
Why?
|
| Tin | 1 | 2016 | 16 | 0.140 |
Why?
|
| Tachycardia, Ventricular | 2 | 2009 | 153 | 0.140 |
Why?
|
| Absorptiometry, Photon | 1 | 2017 | 83 | 0.140 |
Why?
|
| Inhalation | 1 | 2016 | 11 | 0.140 |
Why?
|
| Hyperostosis, Diffuse Idiopathic Skeletal | 1 | 2016 | 1 | 0.140 |
Why?
|
| Arterial Pressure | 1 | 2017 | 47 | 0.140 |
Why?
|
| Age Factors | 6 | 2017 | 1864 | 0.140 |
Why?
|
| Pneumonectomy | 3 | 2022 | 79 | 0.140 |
Why?
|
| Consensus | 3 | 2022 | 211 | 0.140 |
Why?
|
| Osteoporotic Fractures | 1 | 2016 | 9 | 0.140 |
Why?
|
| Aorta, Abdominal | 1 | 2017 | 97 | 0.140 |
Why?
|
| Pregnancy Complications | 1 | 2019 | 286 | 0.140 |
Why?
|
| Coronary Restenosis | 1 | 2016 | 42 | 0.140 |
Why?
|
| Asia | 1 | 2016 | 59 | 0.140 |
Why?
|
| Area Under Curve | 3 | 2019 | 238 | 0.130 |
Why?
|
| United States | 4 | 2017 | 7367 | 0.130 |
Why?
|
| Young Adult | 4 | 2020 | 5717 | 0.130 |
Why?
|
| Body Mass Index | 4 | 2013 | 867 | 0.130 |
Why?
|
| Myocardial Reperfusion Injury | 1 | 2016 | 84 | 0.130 |
Why?
|
| Carcinoma, Squamous Cell | 3 | 2016 | 629 | 0.130 |
Why?
|
| Acute Coronary Syndrome | 1 | 2017 | 195 | 0.130 |
Why?
|
| Carcinoma, Hepatocellular | 1 | 2018 | 163 | 0.130 |
Why?
|
| Peripheral Arterial Disease | 1 | 2017 | 83 | 0.130 |
Why?
|
| Radiation Protection | 2 | 2014 | 71 | 0.130 |
Why?
|
| Heart Diseases | 1 | 2018 | 276 | 0.130 |
Why?
|
| Incidental Findings | 2 | 2013 | 42 | 0.130 |
Why?
|
| Meglumine | 1 | 2015 | 16 | 0.130 |
Why?
|
| Proportional Hazards Models | 5 | 2017 | 792 | 0.130 |
Why?
|
| Lumbar Vertebrae | 1 | 2016 | 112 | 0.130 |
Why?
|
| Osteoporosis | 1 | 2016 | 88 | 0.130 |
Why?
|
| Lower Extremity | 1 | 2017 | 153 | 0.130 |
Why?
|
| Practice Patterns, Physicians' | 1 | 2020 | 504 | 0.130 |
Why?
|
| Spirometry | 4 | 2017 | 47 | 0.130 |
Why?
|
| Thorax | 1 | 2015 | 49 | 0.130 |
Why?
|
| Cost-Benefit Analysis | 3 | 2023 | 504 | 0.120 |
Why?
|
| Arrhythmias, Cardiac | 1 | 2016 | 239 | 0.120 |
Why?
|
| Cancer Survivors | 1 | 2017 | 146 | 0.120 |
Why?
|
| Respiration Disorders | 1 | 2014 | 20 | 0.120 |
Why?
|
| Radiography | 3 | 2020 | 572 | 0.120 |
Why?
|
| Cardiotonic Agents | 2 | 2005 | 71 | 0.120 |
Why?
|
| Breast | 1 | 2015 | 137 | 0.120 |
Why?
|
| Myocardial Contraction | 1 | 2015 | 383 | 0.120 |
Why?
|
| Mitral Valve | 1 | 2015 | 166 | 0.120 |
Why?
|
| Antibodies, Monoclonal | 1 | 2016 | 511 | 0.120 |
Why?
|
| Comorbidity | 5 | 2019 | 1426 | 0.120 |
Why?
|
| Ventricular Remodeling | 1 | 2016 | 318 | 0.110 |
Why?
|
| Matched-Pair Analysis | 1 | 2013 | 25 | 0.110 |
Why?
|
| Optical Imaging | 1 | 2013 | 46 | 0.110 |
Why?
|
| Endoscopic Ultrasound-Guided Fine Needle Aspiration | 1 | 2013 | 16 | 0.110 |
Why?
|
| Lipids | 2 | 2013 | 298 | 0.110 |
Why?
|
| Biomarkers | 3 | 2015 | 1593 | 0.110 |
Why?
|
| Aorta | 2 | 2022 | 316 | 0.110 |
Why?
|
| Glycation End Products, Advanced | 1 | 2013 | 125 | 0.110 |
Why?
|
| Airway Obstruction | 1 | 2013 | 49 | 0.110 |
Why?
|
| Diabetes Mellitus, Type 2 | 1 | 2022 | 1085 | 0.110 |
Why?
|
| Carcinoma | 1 | 2014 | 215 | 0.110 |
Why?
|
| Colorectal Neoplasms | 1 | 2018 | 561 | 0.110 |
Why?
|
| Mammography | 1 | 2015 | 310 | 0.100 |
Why?
|
| Pulmonary Ventilation | 1 | 2012 | 28 | 0.100 |
Why?
|
| Quality-Adjusted Life Years | 2 | 2023 | 106 | 0.100 |
Why?
|
| Stents | 1 | 2016 | 657 | 0.100 |
Why?
|
| X-Ray Microtomography | 1 | 2011 | 50 | 0.100 |
Why?
|
| Computer Simulation | 2 | 2013 | 706 | 0.090 |
Why?
|
| Total Lung Capacity | 3 | 2016 | 14 | 0.090 |
Why?
|
| Disease-Free Survival | 4 | 2015 | 349 | 0.090 |
Why?
|
| Aging | 1 | 2017 | 911 | 0.090 |
Why?
|
| Skin | 1 | 2013 | 451 | 0.090 |
Why?
|
| Organs at Risk | 2 | 2021 | 9 | 0.090 |
Why?
|
| Referral and Consultation | 1 | 2013 | 383 | 0.090 |
Why?
|
| Models, Theoretical | 1 | 2013 | 384 | 0.090 |
Why?
|
| Stroke | 1 | 2022 | 2163 | 0.090 |
Why?
|
| Evidence-Based Medicine | 1 | 2012 | 438 | 0.090 |
Why?
|
| Neoplasm Invasiveness | 2 | 2021 | 369 | 0.080 |
Why?
|
| Emergency Service, Hospital | 1 | 2015 | 711 | 0.080 |
Why?
|
| Ventricular Fibrillation | 1 | 2009 | 85 | 0.080 |
Why?
|
| Patient Selection | 1 | 2012 | 592 | 0.080 |
Why?
|
| Respiratory Function Tests | 3 | 2013 | 123 | 0.080 |
Why?
|
| Lung Volume Measurements | 2 | 2021 | 19 | 0.080 |
Why?
|
| Image Interpretation, Computer-Assisted | 3 | 2017 | 237 | 0.070 |
Why?
|
| Cohort Studies | 3 | 2022 | 2358 | 0.070 |
Why?
|
| Cardiology | 1 | 2008 | 140 | 0.070 |
Why?
|
| Sex Factors | 3 | 2020 | 1266 | 0.070 |
Why?
|
| Death, Sudden, Cardiac | 1 | 2007 | 141 | 0.070 |
Why?
|
| Vital Capacity | 2 | 2017 | 43 | 0.070 |
Why?
|
| Survival Rate | 3 | 2017 | 1056 | 0.070 |
Why?
|
| Alcoholic Beverages | 1 | 2004 | 18 | 0.060 |
Why?
|
| Causality | 2 | 2014 | 82 | 0.060 |
Why?
|
| Electrocardiography, Ambulatory | 2 | 2019 | 34 | 0.060 |
Why?
|
| Residual Volume | 2 | 2014 | 3 | 0.060 |
Why?
|
| Kaplan-Meier Estimate | 2 | 2017 | 536 | 0.060 |
Why?
|
| Ventricular Function, Left | 2 | 2018 | 481 | 0.060 |
Why?
|
| Heart Failure | 1 | 2012 | 1180 | 0.060 |
Why?
|
| Heart Atria | 2 | 2016 | 206 | 0.050 |
Why?
|
| Reference Standards | 1 | 2022 | 115 | 0.050 |
Why?
|
| Life Style | 1 | 2004 | 338 | 0.050 |
Why?
|
| Cardiotoxicity | 1 | 2021 | 12 | 0.050 |
Why?
|
| Arteriosclerosis | 1 | 2002 | 137 | 0.050 |
Why?
|
| Chemoradiotherapy, Adjuvant | 1 | 2021 | 33 | 0.050 |
Why?
|
| Socioeconomic Factors | 1 | 2004 | 955 | 0.050 |
Why?
|
| Bronchoscopy | 1 | 2023 | 147 | 0.050 |
Why?
|
| Radiotherapy Dosage | 1 | 2021 | 125 | 0.050 |
Why?
|
| Child, Preschool | 2 | 2022 | 3187 | 0.050 |
Why?
|
| Clinical Decision-Making | 1 | 2022 | 109 | 0.050 |
Why?
|
| Respiration | 1 | 2021 | 91 | 0.050 |
Why?
|
| South Carolina | 2 | 2019 | 2752 | 0.050 |
Why?
|
| Research Design | 2 | 2017 | 729 | 0.050 |
Why?
|
| Stroke Volume | 2 | 2015 | 586 | 0.040 |
Why?
|
| Personal Protective Equipment | 1 | 2020 | 27 | 0.040 |
Why?
|
| Cancer Care Facilities | 1 | 2020 | 32 | 0.040 |
Why?
|
| Adenocarcinoma | 2 | 2016 | 475 | 0.040 |
Why?
|
| Medical Overuse | 1 | 2020 | 28 | 0.040 |
Why?
|
| Risk | 2 | 2013 | 563 | 0.040 |
Why?
|
| Diagnostic Tests, Routine | 1 | 2020 | 51 | 0.040 |
Why?
|
| Age Distribution | 2 | 2014 | 320 | 0.040 |
Why?
|
| Tissue Survival | 1 | 2019 | 22 | 0.040 |
Why?
|
| Survivors | 1 | 2021 | 256 | 0.040 |
Why?
|
| Adolescent | 3 | 2019 | 8912 | 0.040 |
Why?
|
| Disinfection | 1 | 2020 | 112 | 0.040 |
Why?
|
| Administration, Intravenous | 1 | 2019 | 89 | 0.040 |
Why?
|
| Rest | 1 | 2019 | 78 | 0.040 |
Why?
|
| Analysis of Variance | 2 | 2017 | 1040 | 0.040 |
Why?
|
| Proof of Concept Study | 1 | 2018 | 38 | 0.040 |
Why?
|
| Diabetes, Gestational | 1 | 2019 | 81 | 0.040 |
Why?
|
| Cardiovascular System | 1 | 2019 | 85 | 0.040 |
Why?
|
| Statistics, Nonparametric | 2 | 2012 | 306 | 0.040 |
Why?
|
| Margins of Excision | 1 | 2018 | 15 | 0.040 |
Why?
|
| Patient Safety | 1 | 2020 | 202 | 0.040 |
Why?
|
| Radiopharmaceuticals | 1 | 2018 | 114 | 0.040 |
Why?
|
| Models, Animal | 1 | 2018 | 252 | 0.040 |
Why?
|
| Pilot Projects | 1 | 2021 | 1342 | 0.040 |
Why?
|
| Lung Diseases | 1 | 2019 | 175 | 0.040 |
Why?
|
| Pre-Eclampsia | 1 | 2019 | 202 | 0.040 |
Why?
|
| Airway Resistance | 1 | 2017 | 7 | 0.040 |
Why?
|
| Survival Analysis | 2 | 2012 | 714 | 0.040 |
Why?
|
| Ultrasonography | 2 | 2013 | 453 | 0.040 |
Why?
|
| Radiotherapy | 1 | 2017 | 86 | 0.040 |
Why?
|
| Decision Support Techniques | 1 | 2018 | 191 | 0.040 |
Why?
|
| Hypertrophy | 1 | 2016 | 89 | 0.030 |
Why?
|
| Angina, Unstable | 1 | 2016 | 50 | 0.030 |
Why?
|
| Regional Blood Flow | 1 | 2017 | 168 | 0.030 |
Why?
|
| Clinical Protocols | 1 | 2017 | 172 | 0.030 |
Why?
|
| Cluster Analysis | 1 | 2017 | 219 | 0.030 |
Why?
|
| False Negative Reactions | 1 | 2016 | 63 | 0.030 |
Why?
|
| Program Evaluation | 1 | 2018 | 502 | 0.030 |
Why?
|
| Child | 2 | 2020 | 6405 | 0.030 |
Why?
|
| Communication | 1 | 2018 | 329 | 0.030 |
Why?
|
| Endothelium, Vascular | 1 | 2018 | 371 | 0.030 |
Why?
|
| Artifacts | 1 | 2016 | 125 | 0.030 |
Why?
|
| Microscopy, Fluorescence | 1 | 2016 | 261 | 0.030 |
Why?
|
| Interleukin-6 | 1 | 2016 | 330 | 0.030 |
Why?
|
| Tunica Intima | 2 | 2007 | 59 | 0.030 |
Why?
|
| Diabetes Mellitus | 2 | 2013 | 694 | 0.030 |
Why?
|
| Pulmonary Diffusing Capacity | 1 | 2014 | 12 | 0.030 |
Why?
|
| Bronchial Neoplasms | 1 | 2014 | 12 | 0.030 |
Why?
|
| Dissection | 1 | 2014 | 29 | 0.030 |
Why?
|
| Delayed Diagnosis | 1 | 2014 | 39 | 0.030 |
Why?
|
| Cadaver | 1 | 2014 | 136 | 0.030 |
Why?
|
| Pleural Effusion | 1 | 2014 | 74 | 0.030 |
Why?
|
| Surveys and Questionnaires | 2 | 2017 | 2800 | 0.030 |
Why?
|
| Lymphatic Metastasis | 1 | 2014 | 274 | 0.030 |
Why?
|
| Kidney Function Tests | 1 | 2013 | 114 | 0.030 |
Why?
|
| Bronchography | 1 | 2013 | 5 | 0.030 |
Why?
|
| Pregnancy | 1 | 2019 | 2334 | 0.030 |
Why?
|
| Monitoring, Physiologic | 1 | 2014 | 219 | 0.030 |
Why?
|
| Primary Health Care | 1 | 2018 | 703 | 0.030 |
Why?
|
| Renal Insufficiency | 1 | 2013 | 121 | 0.030 |
Why?
|
| Germany | 1 | 2012 | 67 | 0.030 |
Why?
|
| Clinical Trials as Topic | 1 | 2016 | 848 | 0.030 |
Why?
|
| Natriuretic Peptide, Brain | 1 | 2012 | 101 | 0.020 |
Why?
|
| Aorta, Thoracic | 1 | 2013 | 211 | 0.020 |
Why?
|
| Phenotype | 1 | 2013 | 947 | 0.020 |
Why?
|
| Mice, Inbred C57BL | 1 | 2016 | 2791 | 0.020 |
Why?
|
| Chronic Disease | 1 | 2014 | 1330 | 0.020 |
Why?
|
| Peptide Fragments | 1 | 2012 | 483 | 0.020 |
Why?
|
| Carcinoma, Large Cell | 1 | 2008 | 6 | 0.020 |
Why?
|
| North America | 1 | 2008 | 112 | 0.020 |
Why?
|
| Troponin | 1 | 2007 | 25 | 0.020 |
Why?
|
| Models, Anatomic | 1 | 2007 | 51 | 0.020 |
Why?
|
| Tunica Media | 1 | 2007 | 33 | 0.020 |
Why?
|
| Energy Intake | 1 | 2008 | 123 | 0.020 |
Why?
|
| Cell Transformation, Neoplastic | 1 | 2008 | 235 | 0.020 |
Why?
|
| Educational Status | 1 | 2008 | 273 | 0.020 |
Why?
|
| Infant, Newborn | 1 | 2012 | 2455 | 0.020 |
Why?
|
| Infant | 1 | 2012 | 2891 | 0.020 |
Why?
|
| Sex Characteristics | 1 | 2008 | 295 | 0.020 |
Why?
|
| Carotid Stenosis | 1 | 2007 | 163 | 0.020 |
Why?
|
| Diet | 1 | 2008 | 514 | 0.010 |
Why?
|
| Treatment Outcome | 1 | 2016 | 7029 | 0.010 |
Why?
|
| Motion | 1 | 2003 | 24 | 0.010 |
Why?
|
| Interviews as Topic | 1 | 2004 | 392 | 0.010 |
Why?
|
| Blood Pressure | 1 | 2007 | 1451 | 0.010 |
Why?
|